Amy McBride Wendell - 16 Dec 2025 Form 4 Insider Report for Axogen, Inc. (AXGN)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
17 Dec 2025, 16:25:23 UTC
Prior SEC filing
20 Jun 2025
Next SEC filing
02 Mar 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Marc Began, attorney-in-fact for Amy McBride-Wendell

Key filing fact

Amy McBride Wendell filed Form 4 for Axogen, Inc. (AXGN) on 17 Dec 2025.

Key facts

  • This page summarizes Amy McBride Wendell's Form 4 filing for Axogen, Inc. (AXGN).
  • 9 reported transactions and 3 derivative rows are listed below.
  • Accepted by SEC: 17 Dec 2025, 16:25.

Change

  • Previous filing in this sequence was filed on 20 Jun 2025.
  • Current net transaction value: -$978,503.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001400568 Primary reporting owner

Wendell Amy McBride

Relationship
Director
Address
C/O AXOGEN, INC. 13631 PROGRESS BLVD., SUITE 400, ALACHUA
Signature
/s/ Marc Began, attorney-in-fact for Amy McBride-Wendell
Signature date
17 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AXGN transaction

Common Stock

Options Exercise

Transaction value
$44,750
Shares
+5,000
Change %
+5.3%
Price
$8.95
Shares after
98,826
Date
16 Dec 2025
Ownership
Direct
AXGN transaction

Common Stock

Options Exercise

Transaction value
$128,747
Shares
+20,436
Change %
+21%
Price
$6.30
Shares after
119,262
Date
16 Dec 2025
Ownership
Direct
AXGN transaction

Common Stock

Options Exercise

Transaction value
$128,466
Shares
+18,248
Change %
+15%
Price
$7.04
Shares after
137,510
Date
16 Dec 2025
Ownership
Direct
AXGN transaction

Common Stock

Sale

Transaction value
$146,560
Shares
-5,000
Change %
-3.6%
Price
$29.31
Shares after
132,510
Date
16 Dec 2025
Ownership
Direct
Footnotes
F1
AXGN transaction

Common Stock

Sale

Transaction value
$599,020
Shares
-20,436
Change %
-15%
Price
$29.31
Shares after
112,074
Date
16 Dec 2025
Ownership
Direct
Footnotes
F1
AXGN transaction

Common Stock

Sale

Transaction value
$534,885
Shares
-18,248
Change %
-16%
Price
$29.31
Shares after
93,826
Date
16 Dec 2025
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AXGN transaction Derivative

Stock Option (right to purchase)

Options Exercise

Transaction value
$0
Shares
-5,000
Change %
-100%
Price
$0.000000
Shares after
0
Date
16 Dec 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
5,000
Exercise price
$8.95
Footnotes
F2
AXGN transaction Derivative

Stock Option (right to purchase)

Options Exercise

Transaction value
$0
Shares
-20,436
Change %
-100%
Price
$0.000000
Shares after
0
Date
16 Dec 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
20,436
Exercise price
$6.30
Footnotes
F3
AXGN transaction Derivative

Stock Option (right to purchase)

Options Exercise

Transaction value
$0
Shares
-18,248
Change %
-100%
Price
$0.000000
Shares after
0
Date
16 Dec 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
18,248
Exercise price
$7.04
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $28.99 to $29.63 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Footnote F2

Board of Directors' non-qualified stock option grant that vested in full May 26, 2017.

Footnote F3

Board of Directors' non-qualified stock option grant that vested in full September 1, 2024.

Footnote F4

Board of Directors' non-qualified stock option grant that vested in full June 6, 2025.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .